Effective dose of Remimazolam Tosilate inhibiting responses to artificial airway insertion in different gender

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048631

Enrollment

Unknown

Registered

2021-07-12

Start date

2021-07-13

Completion date

Unknown

Last updated

2022-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug dosage of remazolam during induction of anesthesia

Interventions

Group 1:drug concentration1

Group 2:Drug concentration 2

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. ASA I-II; 2.BMI 20-25kg/m2; 3.Patients aged between 18 and 60 years.

Exclusion criteria

Exclusion criteria: 1. Past history of allergy to benzodiazepines; 2. Past history of mental illness; 3. Preoperative SBP>=180mmHg, DBP>=110mmHg; 4. Preoperative history of tachycardia or HR>=110 beats/min; 5. Predictably difficult airway.

Design outcomes

Primary

Measure	Time frame
blood pressure;heart rate;	—

Countries

China

Contacts

Public ContactZhang Wei

The First Affiliated Hospital of Zhengzhou University

chalou666666@126.com+86 13838390767

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026